butylscopolammonium bromide has been researched along with imatinib mesylate in 1 studies
Studies (butylscopolammonium bromide) | Trials (butylscopolammonium bromide) | Recent Studies (post-2010) (butylscopolammonium bromide) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
---|---|---|---|---|---|
695 | 165 | 149 | 11,477 | 960 | 5,773 |
Protein | Taxonomy | butylscopolammonium bromide (IC50) | imatinib mesylate (IC50) |
---|---|---|---|
Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hino, M; Koh, KR; Nakamae, H; Nakane, T; Nakao, T; Terada, Y; Yamane, T; Yoshida, N | 1 |
1 other study(ies) available for butylscopolammonium bromide and imatinib mesylate
Article | Year |
---|---|
[Chronic myelogenous leukemia complicated by drug-induced agranulocytosis].
Topics: Aged; Agranulocytosis; Benzamides; Butylscopolammonium Bromide; Colonoscopy; Female; Flumazenil; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Piperazines; Premedication; Pyrimidines; Treatment Outcome | 2011 |